vs
Side-by-side financial comparison of Organon & Co. (OGN) and PVH CORP. (PVH). Click either name above to swap in a different company.
PVH CORP. is the larger business by last-quarter revenue ($2.3B vs $1.5B, roughly 1.6× Organon & Co.). Organon & Co. runs the higher net margin — 10.0% vs 0.2%, a 9.8% gap on every dollar of revenue. On growth, PVH CORP. posted the faster year-over-year revenue change (1.7% vs -3.5%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
PVH Corp., formerly known as the Phillips-Van Heusen Corporation, is an American clothing company which owns brands such as Tommy Hilfiger and Calvin Klein. The company also licenses brands such as Kenneth Cole New York and Michael Kors.
OGN vs PVH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.3B |
| Net Profit | $146.0M | $4.2M |
| Gross Margin | 53.6% | 56.3% |
| Operating Margin | — | 7.9% |
| Net Margin | 10.0% | 0.2% |
| Revenue YoY | -3.5% | 1.7% |
| Net Profit YoY | 67.8% | -96.8% |
| EPS (diluted) | $0.55 | $0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $2.3B | ||
| Q3 25 | $1.6B | $2.2B | ||
| Q2 25 | $1.6B | $2.0B | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — |
| Q1 26 | $146.0M | — | ||
| Q4 25 | $-205.0M | $4.2M | ||
| Q3 25 | $160.0M | $224.2M | ||
| Q2 25 | $145.0M | $-44.8M | ||
| Q1 25 | $87.0M | — | ||
| Q4 24 | $109.0M | — | ||
| Q3 24 | $359.0M | — | ||
| Q2 24 | $195.0M | — |
| Q1 26 | 53.6% | — | ||
| Q4 25 | 49.2% | 56.3% | ||
| Q3 25 | 53.5% | 57.7% | ||
| Q2 25 | 54.8% | 58.6% | ||
| Q1 25 | 55.6% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 58.3% | — | ||
| Q2 24 | 58.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.8% | 7.9% | ||
| Q3 25 | 15.2% | 6.1% | ||
| Q2 25 | 14.4% | -16.7% | ||
| Q1 25 | 6.7% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 13.1% | — | ||
| Q2 24 | 14.6% | — |
| Q1 26 | 10.0% | — | ||
| Q4 25 | -13.6% | 0.2% | ||
| Q3 25 | 10.0% | 10.3% | ||
| Q2 25 | 9.1% | -2.3% | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 6.8% | — | ||
| Q3 24 | 22.7% | — | ||
| Q2 24 | 12.1% | — |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $-0.78 | $0.09 | ||
| Q3 25 | $0.61 | $4.63 | ||
| Q2 25 | $0.56 | $-0.88 | ||
| Q1 25 | $0.33 | — | ||
| Q4 24 | $0.42 | — | ||
| Q3 24 | $1.38 | — | ||
| Q2 24 | $0.75 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $158.2M |
| Total DebtLower is stronger | — | $2.3B |
| Stockholders' EquityBook value | — | $4.9B |
| Total Assets | — | $11.4B |
| Debt / EquityLower = less leverage | — | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $574.0M | $158.2M | ||
| Q3 25 | $672.0M | $248.8M | ||
| Q2 25 | $599.0M | $191.0M | ||
| Q1 25 | $547.0M | — | ||
| Q4 24 | $675.0M | — | ||
| Q3 24 | $763.0M | — | ||
| Q2 24 | $704.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $8.6B | $2.3B | ||
| Q3 25 | $8.8B | $2.3B | ||
| Q2 25 | $8.9B | $2.2B | ||
| Q1 25 | $9.0B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $8.7B | — | ||
| Q2 24 | $8.7B | — |
| Q1 26 | — | — | ||
| Q4 25 | $752.0M | $4.9B | ||
| Q3 25 | $906.0M | $4.9B | ||
| Q2 25 | $733.0M | $4.6B | ||
| Q1 25 | $542.0M | — | ||
| Q4 24 | $472.0M | — | ||
| Q3 24 | $493.0M | — | ||
| Q2 24 | $144.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $12.9B | $11.4B | ||
| Q3 25 | $13.6B | $11.6B | ||
| Q2 25 | $13.5B | $10.7B | ||
| Q1 25 | $13.2B | — | ||
| Q4 24 | $13.1B | — | ||
| Q3 24 | $12.8B | — | ||
| Q2 24 | $12.2B | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.49× | 0.46× | ||
| Q3 25 | 9.74× | 0.47× | ||
| Q2 25 | 12.14× | 0.48× | ||
| Q1 25 | 16.52× | — | ||
| Q4 24 | 18.81× | — | ||
| Q3 24 | 17.75× | — | ||
| Q2 24 | 60.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-44.5M |
| Free Cash FlowOCF − Capex | — | $-85.1M |
| FCF MarginFCF / Revenue | — | -3.7% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | — | -10.60× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $141.0M | $-44.5M | ||
| Q3 25 | $264.0M | $213.1M | ||
| Q2 25 | $220.0M | $-71.4M | ||
| Q1 25 | $75.0M | — | ||
| Q4 24 | $390.0M | — | ||
| Q3 24 | $141.0M | — | ||
| Q2 24 | $332.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $96.0M | $-85.1M | ||
| Q3 25 | $218.0M | $181.9M | ||
| Q2 25 | $181.0M | $-98.1M | ||
| Q1 25 | $43.0M | — | ||
| Q4 24 | $335.0M | — | ||
| Q3 24 | $99.0M | — | ||
| Q2 24 | $300.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | -3.7% | ||
| Q3 25 | 13.6% | 8.4% | ||
| Q2 25 | 11.4% | -4.9% | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 6.3% | — | ||
| Q2 24 | 18.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 1.8% | ||
| Q3 25 | 2.9% | 1.4% | ||
| Q2 25 | 2.4% | 1.3% | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 3.5% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 2.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -10.60× | ||
| Q3 25 | 1.65× | 0.95× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
PVH
| Sales Channel Salesto Wholesale Customers | $1.0B | 44% |
| Sales Channel Sales To Owned And Operated Retail Customers | $868.0M | 38% |
| Sales Channel Sales To Owned And Operated Digital Retail Customers | $186.6M | 8% |
| Licensing | $99.5M | 4% |
| Other | $75.8M | 3% |
| Heritage Brands | $51.3M | 2% |
